Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Increases immune system health: By promoting a healthy gut, this service also supports and strengthens your overall immune system, enhancing your body's natural defenses
S2CID 21618233
Digestive Issues Some people may experience gastrointestinal discomfort, such as nausea, cramps, diarrhea, or bloating
As a 39-amino acid synthetic peptide, tirzepatide is engineered on a modified GIP backbone with integrated GLP-1 receptor activity, representing a fundamentally different pharmacological approach from selective GLP-1 agonists such as semaglutide